Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients with Cystic Fibrosis

http://academiccme.com/wp-content/uploads/2017/01/910655-125-x-125.jpg

Course Information

Therapautic Area: Pulmonolgy
Format(s): Webcast
Credit(s): 2.00 AMA PRA Category 1 Credit(s)™
Activity Dates: January 10, 2017 - January 9, 2018

 

Program Overview

The content for this activity is based on the satellite symposium, “Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis”, that was presented at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida on October 28, 2016. The content highlights the latest advancements, particularly in CFTR-based therapeutics, for the treatment of patients with cystic fibrosis. Expert faculty discuss the most up-to-date analysis for clinical decision-making, including updates on assessment, monitoring, and management of patients treated with CFTR modulator therapies. The goal of this activity is to increase the knowledge and competencies of the multidisciplinary team involved in the management of patients with CF, and provide strategies for improving the lives of patients. Upon completion of this activity, healthcare providers will be better equipped with imperative information for creating more effective personalized treatment plans and improving patient outcomes.

Target Audience

This activity is designed for physicians, nurses, and other healthcare professionals involved in the management of patients with cystic fibrosis.

Educational Objectives

  1. Review and analyze the current clinical trial data for CFTR modulator therapeutics to develop effective individualized treatment plans.
  2. Discuss the details of real-world outcomes for patients treated with CFTR-based therapeutics.
  3. Apply the principles of early diagnosis and early pharmaco-therapeutic intervention to the pediatric cystic fibrosis population.
  4. Understand the science of developing therapeutic options for treating a larger population of cystic fibrosis patients.

Faculty

clancy-headshotJP Clancy, MD (Chair)
Professor and Gunnar Esiason/Cincinnati Bell Chair
Director, Pulmonary Medicine Research
Medical Director, Office of Clinical and Translational Research
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

 



benitez-headshotDebbie S. Benitez, RN, MSN, ACNP-BC
Pulmonary Nurse Practitioner/Nurse Coordinator
Center for Cystic Fibrosis
Keck Medical Center of USC
Los Angeles, California

 

 

fajac-headshotIsabelle Fajac, MD, PhD
Professor of Physiology
Head of the Respiratory Physiology Unit
Adult CF Center
Cochin Hospital
Sorbonne Paris Cité University
Paris, France

 

jain-headshotManu Jain, MD
Professor of Medicine & Pediatrics
Director of Adult CF
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

 

 

rowe-headshotSteven M. Rowe, MD
Professor, Department of Medicine, Pediatrics, and Cell Developmental & Integrative Biology
Director, Gregory Fleming James
Cystic Fibrosis Research Center
Gwaltney Endowed Chair Medical Research
University of Alabama at Birmingham
Birmingham, Alabama


sawicki-headshotGregory Sawicki, MD, MPH
Director, Cystic Fibrosis Center
Boston Children’s Hospital
Assistant Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

 


Registration



This CME activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

eocme acme logo